Opinion|Videos|February 18, 2025

Future Directions of BCG-Unresponsive NMIBC Management

A panelist discusses how urologists considering newer treatment modalities for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) should be encouraged by positive clinical trial data while ensuring proper training, patient selection, and establishment of treatment protocols in their practice.

  • What advice do you have for urologists considering the adoption of newer treatment modalities for BCG-unresponsive NMIBC, especially in light of the positive clinical trial data?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME